Cordis Corporation Announces One-Year Results From The STROLL Trial

Cordis Corporation today announced the presentation of the STROLL study results at the Late Breaking Clinical Trials session at VIVA 2012.

Michael R. Jaff, DO, presented the results of the STROLL study ( S.M.A.R.T. ® Nitinol Self-Expanding Stent in the TReatment of Obstructive Superficia L Femora L Artery Disease) on behalf of the study investigators. The STROLL study assessed the safety and efficacy of the S.M.A.R.T.® Nitinol Self-Expandable Stent System (S.M.A.R.T.® Stent) in treating patients with obstructive superficial femoral artery (SFA) disease.

“The STROLL trial demonstrates one year patency rates of ~81% and a very low fracture rate,” said Dr. William A. Gray, Director of Endovascular Services, Cardiovascular Research Foundation, New York. “These outcomes both meet and exceed our expectations for patients with symptomatic disease of the superficial femoral artery.”

In the study, the average lesion length was 77 mm, 23.6% of patients presented with total occlusions and 47% of patients were diabetic. Freedom from clinically driven target lesion revascularization (TLR) at one year was 87.4%. The 12-month primary patency rate for the S.M.A.R.T.® Stent was 81.7% by Kaplan Meier estimate. The primary duplex patency rate (PSVR>/=2.5) was 81.1%. There were no major adverse events at 30 days after the initial index procedure. There was also a low rate of stent fractures noted at 12 months (1.8%). All stent fractures were Type I, least severe, there were no incidents of more severe stent fractures (Type II-V).

“We are very pleased with the results of the STROLL study,” said Shlomi Nachman, Worldwide President, Cordis Corporation, “As it achieved the protocol’s prospective primary safety and efficacy endpoints for the S.M.A.R.T.® Stent in the treatment of peripheral artery disease.”

STROLL is a multicenter, non-randomized, single-arm, prospective trial comparing efficacy and safety of the S.M.A.R.T.® Stent with a previously published objective performance goal. Patients ≥30 years of age with de novo or restenotic native SFA lesion(s) or total occlusions with length ≥ 4.0 cm to ≤ 15.0 cm, and reference vessel diameters of ≥ 4.0 mm to ≤ 6.0 mm were included in the study. The 12-month primary patency endpoint was defined as no relevant flow reduction by duplex ultrasonography (DUS) determined by independent core lab, and no interim clinically driven TLR. The primary safety endpoint was 30-day freedom from major adverse events, a composite of all-cause death, index limb amputation and clinically driven TLR. Secondary endpoints cover a variety of morphological, clinical and hemodynamic outcomes.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'

Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell'

The Best Companies for Women